These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 37005878)

  • 1. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
    BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
    Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
    BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cuproptosis-Related LncRNA Signature for Predicting Prognosis of Hepatocellular Carcinoma: A Comprehensive Analysis.
    Chen Q; Sun T; Wang G; Zhang M; Zhu Y; Shi X; Ding Z
    Dis Markers; 2022; 2022():3265212. PubMed ID: 36452343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma.
    Li D; Jin S; Chen P; Zhang Y; Li Y; Zhong C; Fan X; Lin H
    Front Immunol; 2022; 13():991604. PubMed ID: 36685508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma.
    Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC
    World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cuproptosis-related lncRNA signature for predicting prognosis and immune response in hepatocellular carcinoma.
    Wu J; Yao J; Jia S; Yao X; Shao J; Cao W; Ma S; Yao X; Li H
    Heliyon; 2023 Sep; 9(9):e19352. PubMed ID: 37810122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
    BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and systematic evaluation of a machine learning-based cuproptosis-related lncRNA score signature to predict the response to immunotherapy in hepatocellular carcinoma.
    Lu D; Liao J; Cheng H; Ma Q; Wu F; Xie F; He Y
    Front Immunol; 2023; 14():1097075. PubMed ID: 36761763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
    Huang Y; Gong P; Su L; Zhang M
    Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
    Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
    World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cuproptosis-related lncRNAs predict the prognosis and immune response in hepatocellular carcinoma.
    Zhang Q; Huang Y; Xia Y; Liu Y; Gan J
    Clin Exp Med; 2023 Oct; 23(6):2051-2064. PubMed ID: 36153416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
    Xu M; Mu J; Wang J; Zhou Q; Wang J
    Front Oncol; 2022; 12():961213. PubMed ID: 35965536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y; Zhang Q; Liu F; Quan J
    Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.